Lacombe, Jérôme
Brengues, Muriel
Mangé, Alain
Bourgier, Céline
Gourgou, Sophie
Pèlegrin, André
Ozsahin, Mahmut
Solassol, Jérôme
Azria, David http://orcid.org/0000-0002-7533-2988
Funding for this research was provided by:
Institut National Du Cancer (INCa-DGOS-Inserm 6045)
Article History
Received: 10 March 2019
Accepted: 1 August 2019
First Online: 9 August 2019
Ethics approval and consent to participate
: All patients were selected from two prospective clinical trials (COHORT and PHRC 2005) and accepted to participate in this translational sub-study initially planned in the protocol. These studies were approved by our local ethical committee and registered in clinicaltrials.gov (NCT00208273 and NCT00893035, respectively).
: Not applicable
: ICM, CHU Montpellier and University of Montpellier own a patent (WO2014154854A1) associated with a method for determining radiosensitivity that includes the protein AK2. D. A., J. L., J. S., and A.M. are the inventors. The other authors have no conflict of interest to declare.